Catheter-related Bloodstream Infection (CRBSI) Pipeline Therapies Analysis 2025: Over 5 Companies Driving Innovation Across 5+ Therapies | DelveInsight

DelveInsight's analysis highlights that the Catheter-related Bloodstream Infection (CRBSI) pipeline features over five leading companies actively advancing more than five therapeutic candidates aimed at improving CRBSI management.

DelveInsight's "CRBSI Pipeline Insight 2025" report delivers an in-depth evaluation of ongoing clinical research activities and future growth opportunities within the CRBSI therapeutics landscape.

The Surgical Site Infections Pipeline report offers comprehensive clinical and commercial insights into pipeline candidates ranging from preclinical and discovery stages to marketed products. It includes extensive drug profiles covering mechanisms of action, clinical trial progress, regulatory milestones such as NDA approvals (where applicable), and product development activities. These activities encompass technology platforms, partnerships, mergers and acquisitions, funding updates, regulatory designations, and other key developments related to each product.

Catheter-related Bloodstream Infection (CRBSI) Overview
Catheter-related bloodstream infection (CRBSI) refers to bacteremia that develops as a direct result of an infected intravenous catheter. It remains one of the most serious, frequent, and costly complications associated with central venous catheter use and is recognized as a major contributor to hospital-acquired bloodstream infections. Intravascular catheters play a vital role in contemporary healthcare, particularly for critically ill patients, enabling the delivery of medications, fluids, blood products, parenteral nutrition, and facilitating hemodynamic monitoring.

Among medical devices, central venous catheters (CVCs) pose the highest risk for infection and are closely linked to increased morbidity and mortality rates. These devices represent the primary source of bacteremia and septicemia in hospitalized individuals. Clinical evidence suggests that the likelihood of developing CRBSI is up to 64 times greater with CVCs compared to peripheral venous catheters, underscoring the urgent need for effective preventive and therapeutic strategies.

Request a comprehensive CRBSI pipeline insights report here: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the CRBSI Pipeline Report
• The CRBSI pipeline showcases a competitive and evolving ecosystem, with over 5 companies developing more than 5 investigational therapies.
• Leading players, including Leonard-Meron Biosciences, Inc., along with other emerging developers, are actively assessing innovative treatment options to strengthen the CRBSI therapeutic framework.
• Notable pipeline candidates progressing through various stages of development include Mino-Lok, among others.

Recent Developments in the CRBSI Pipeline Landscape
• In December 2025, CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced interim results for the Company's ongoing real-world evidence study being conducted in conjunction with U.S. Renal Care's (USRC) use of DefenCath in adult hemodialysis patients with central venous catheters. CorMedix and USRC commenced the real-world evidence study upon outpatient commercial launch in July 2024. The study is designed to demonstrate the impact of the broad use of DefenCath in a real-world setting and prospectively assess rates of catheter-related bloodstream infections (CRBSI), as well as hospitalizations secondary to these infections. The study is designed to evaluate these data points for two years. Currently, more than 3,000 patients per month are receiving DefenCath on a routine basis at USRC facilities. CorMedix conducted a preliminary analysis of interim data for approximately 7,000 patients having received at least one dose of DefenCath in Year 1.
• In November 2024, Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company held a constructive in-person Type C meeting with the U.S. Food and Drug Administration (FDA). The meeting followed successful completion of the Company's pivotal Phase 3 clinical trial of Mino-Lok®, a novel catheter lock solution designed to salvage central venous catheters in patients suffering from central line-associated bloodstream infections (CLABSI) or catheter-related bloodstream infections (CRBSI). The primary discussion centered on responses to the FDA's questions related to Mino-Lok's clinical trial data and a pathway to a future submission.

CRBSI Pipeline Analysis
The report offers a detailed assessment covering:
• Comprehensive profiling of key companies engaged in CRBSI drug development.
• Evaluation of pipeline candidates across early, mid, and late stages of clinical development.
• Identification of companies pursuing targeted therapeutic approaches, including both active and discontinued programs.
• In-depth insights into emerging therapies based on development stage, route of administration, molecular type, mechanism of action, therapeutic approach (monotherapy or combination), and biological targets.
• Extensive analysis of strategic collaborations, licensing deals, funding activities, and partnerships between industry players and academic institutions supporting future market expansion.

Access a free sample report on CRBSI pipeline insights here: https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Catheter-Related Bloodstream Infections Competitive Landscape
Emerging CRBSI Therapies
• Mino-Lok - Leonard-Meron Biosciences, Inc.

CRBSI Key Companies
More than five major pharmaceutical and biotechnology companies are currently engaged in developing treatments for catheter-related bloodstream infections. Among these, Leonard-Meron Biosciences, Inc., along with other players, has candidates advancing into late-stage clinical development, including Phase III trials.

Catheter-Related Bloodstream Infections Therapeutic Landscape
DelveInsight's report evaluates over five products across multiple stages, including:
• Late-stage (Phase III)
• Mid-stage (Phase II)
• Early-stage (Phase I)
• Preclinical and discovery-stage candidates
• Discontinued and inactive programs

CRBSI Therapeutic Categorization
The CRBSI pipeline report provides therapeutic assessments based on route of administration, including:
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Pipeline therapies are also classified by molecular type, such as:
• Monoclonal antibodies
• Small molecules
• Peptides

Download sample pages to explore detailed insights into emerging CRBSI therapies, clinical trials, and recent advancements: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

CRBSI Pipeline Therapeutic Assessment Includes
• Assessment by product type
• Evaluation by development stage
• Analysis by route of administration
• Classification by molecule type

Download the CRBSI sample report to gain in-depth insights into the evolving CRBSI treatment market: https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.